Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Becton, Dickinson and Co. (NYSE:BDX) is a multinational medical technology company that manufactures and sells medical devices, instruments, and reagents for healthcare institutions, life science researchers, and the general public worldwide. It will report its Q4 2025 earnings on Nov. 6. Wall Street analysts expect the company to post EPS of $3.92, up from $3.81 in the prior-year period. According to data ...

Core Insights - Zimmer Biomet Holdings (NYSE: ZBH) has experienced a challenging stock performance over the past month, recording single-digit losses, similar to the losses observed in 2025 [1] Company Performance - The stock has faced single-digit losses recently, indicating a tough market environment for the company [1] Analyst Background - Gamu Dave Innocent Pasi, a financial professional with extensive experience in investment research, has a strong background in analyzing financial statements and capital markets [1] - He is recognized for providing actionable trading ideas and well-researched investment recommendations, contributing to reputable publications [1] - Pasi holds a Postgraduate Executive Certificate in Investments and Portfolio Management and a Bachelor of Business Studies Honors degree in Banking and Finance [1] Investment Philosophy - Pasi is passionate about innovative solutions that promote financial inclusion, sustainability, and measurable social impact [1] - He advocates for Responsible Investment and actively incorporates Environmental, Social, and Governance (ESG) principles in investment decision-making [1]

Core Insights - The article discusses the concept of Dividend Kings, which are companies that have increased their dividends for over 50 consecutive years, highlighting their resilience and consistent growth in dividends [4] Group 1: Dividend Kings Overview - Dividend Kings are companies that have a long history of increasing dividends, making them attractive for long-term income investors [4][7] - The article emphasizes the importance of selecting companies with a positive consensus from analysts, focusing on stability and growth potential [1][2] Group 2: Company Profiles AbbVie Inc. (ABBV) - AbbVie reported a revenue increase of approximately 3.7% to $56.33 billion, but net income declined by 12% to around $4.28 billion, resulting in a basic EPS of $2.40 for 2024 [12] - The forward dividend payout is $6.56, with a yield of 6.56% and a payout ratio of 59.92% [13] - Analysts rate AbbVie as a Moderate Buy with a score of 4.21 out of 5, indicating a potential upside of 21.38% from its current price [14][15] Johnson & Johnson (JNJ) - Johnson & Johnson's revenue rose roughly 4.3% to $88.82 billion, but net income declined nearly 60% due to a discontinued operation, resulting in a basic EPS of $5.84 [18] - The forward dividend payout is $5.20, yielding 5.2% with a payout ratio of 49.88% [20] - Analysts rate JNJ as a Moderate Buy with a score of 4.04 out of 5, suggesting an upside potential of 11.5% [21][22] Lowe's Companies (LOW) - Lowe's revenue declined 3% to $83.67 billion, with net income down approximately 10% to $6.96 billion, leading to a basic EPS of $12.25 [26] - The forward dividend is $4.80, yielding 4.80% with a payout ratio of 38.46% [28] - Analysts rate Lowe's as a Moderate Buy with a score of 4.21 out of 5, with a potential upside of 38.5% [29][30] Abbott Laboratories (ABT) - Abbott's revenue increased by 4.5% to $41.95 billion, and net income surged 134% to $13.4 billion, resulting in a basic EPS of $7.67 [33] - The company has declared 399 consecutive quarterly dividends and has increased its payout for 51 consecutive years, with a current yield of 1.77% [34] - Analysts rate Abbott as a Strong Buy with a score of 4.43, indicating a potential upside of 19.2% [36] Coca-Cola Company (KO) - Coca-Cola's revenue for FY'24 was just over $47 billion, up 2.8%, while net income declined slightly by 0.8%, with a basic EPS of $2.47 [38] - The forward dividend is $2.04 annually, yielding just over 3%, with a 21.25% increase in dividends over the past five years [40] - Analysts rate Coca-Cola as a Strong Buy with a score of 4.76, suggesting an upside potential of 28% [40]

"We are pleased with the preliminary FULCRUM-VT acute data, which highlight the potential of Adagio's proprietary ULTC technology to transform treatment for patients with ventricular tachycardia,†said Todd Usen, Chief Executive Officer of Adagio Medical. "On behalf of the entire Adagio Medical team, I want to thank all of the investigators, research coordinators and patients who have supported this study and whose commitment to serving this underserved population of patients will bring us one step closer to ...

Key Takeaways BD announced a multi-year collaboration with Opentrons to automate single-cell sequencing workflows.The deal integrates BD Rhapsody with Opentrons Flex to enable hands-free multiomics experiments.The partnership aims to strengthen BD's BDB business unit and accelerate drug discovery efforts.Becton, Dickinson and Company (BDX) , popularly known as BD, announced a multi-year collaboration with Opentrons Labworks, Inc. on Wednesday. Per the agreement, BD and Opentrons are expected to integrate ro ...

Key Takeaways Wall Street slid on Oct. 9, 2025, as investor uncertainty hit major stock indices. Zacks highlights five low-leverage stocks positioned for stability amid market volatility.ResMed, Safran, Pentair, Casey's, and Leonardo DRS show solid growth and low debt levels.Following a steady rally over the past few days, Wall Street hit a wall on Oct. 9, 2025, as major stock indices took a tumble. As the market gears up for mega banks to release their Q3 numbers next week, uncertainty surrounding the lon ...

Key Takeaways AVO, ELMD, GLDD and CENX were selected for strong net profit margins.Each stock has witnessed upward EPS estimate revisions for the current fiscal.All four picks have a Zacks Rank of 1 or 2 and solid VGM Scores, suggesting further upside potential.Net profit, also referred to as the bottom line, is one of the key tools to determine the financial health of an enterprise. The metric demonstrates a company’s ability to convert per-dollar sales into profits.A low profit margin indicates higher ris ...

Core Insights - Abbott Laboratories (ABT) is set to report its third-quarter 2025 results on October 15, with adjusted earnings per share (EPS) of $1.26 in the last quarter, exceeding the Zacks Consensus Estimate by 0.8% [1][8] Revenue and EPS Estimates - The Zacks Consensus Estimate for Q3 revenues is $11.42 billion, reflecting a 7.4% increase from the previous year [2][8] - The Zacks Consensus Estimate for EPS is $1.30, indicating a 7.4% improvement from the prior year's figure [2][8] Segment Performance Expectations - **Diagnostics**: Revenue growth is expected to be impacted by a decline in COVID-19 testing revenues and volume-based procurement programs in China, with a projected decrease of 4.4% year over year [3][4] - **Established Pharmaceuticals (EPD)**: Strong performance is anticipated across key markets, with a year-over-year revenue increase of 9%, driven by biosimilars as a new growth pillar [5][6] - **Medical Devices**: Expected growth of 13.3% year over year, supported by the Diabetes Care division and the integration of Libre CGM data into Epic's EHR systems [6][11] - **Nutrition**: Anticipated revenue growth of 6.3% year over year, driven by strong sales of adult nutrition brands like Ensure and Glucerna [12] Recent Developments - Abbott's Structural Heart segment is expected to see growth from surgical valves and transcatheter products, bolstered by recent CE Mark and FDA approvals [9][11] - The Rhythm Management arm is gaining traction with the leadless AVEIR pacemaker, supported by favorable clinical data [10] Earnings ESP and Zacks Rank - Abbott has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 3, indicating a neutral outlook for beating estimates [13]

Company Developments - Zimmer Biomet Holdings (ZBH) and its subsidiary Paragon 28 have launched two solutions for complex foot and ankle trauma: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail, enhancing the company's trauma portfolio [1][9] - The Gorilla Pilon Fusion Plating System addresses primary tibiotalar fusion for patients with pilon fractures, which represent approximately 7% to 10% of all tibial fractures [4][5] - The Phantom TTC Trauma Nail expands on the existing Phantom TTC Nail platform, offering enhanced lengths and fixation capabilities for complex trauma cases [7][10] Financial Performance - Following the announcement of the new products, ZBH shares decreased by 0.7%, closing at $98.36 [2] - ZBH has a market capitalization of $19.48 billion and an earnings yield of 8.3%, significantly higher than the industry average of 0.1% [3] Market Outlook - The global foot and ankle device market was valued at $4.76 billion in 2024 and is projected to grow at a compound annual growth rate of 7.1% through 2030, driven by the increasing adoption of minimally invasive treatments and the rising prevalence of conditions like osteoporosis [11] Recent Acquisitions - Zimmer Biomet has completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company, which enhances its suite of orthopedic robotics solutions [12] Stock Performance - Over the past three months, ZBH shares have increased by 3.8%, outperforming the industry growth of 0.2% [13]

Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an additional 180-calendar-day period to regain compliance with the minimum bid price requirement pursuan ...